AMGN

AMGEN INC

Biological Products, (No Diagnostic Substances) · SIC 2836CIK 318154Held by 13 tracked managersEDGAR filings ↗10-K/10-Q ↗

SHARE:X LINKEDIN EMAIL

Revenue FY2025

$36.75B

Net Income FY2025

$7.71B

EPS (Basic, as reported)

$14.33

Net Margin FY2025

21.0%

ROE FY2025

89.1%

Total Equity

$8.66B

Shares Out

541M

Business description

AMGEN INC — Biological Products, (No Diagnostic Substances). Figures are as reported in each year's original 10-K via SEC EDGAR XBRL company facts (FY2007–FY2025; structured XBRL data begins around 2008). Market-price metrics are not part of EDGAR data.

Annual (fiscal years, as reported)USD millions

default rows · click any row to chart itRevenue: 22,991 → 36,751 +5.4% CAGR

Fiscal yearFY2016FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025

Revenue22,99122,84923,74723,36225,42425,97926,32328,19033,42436,751

Cost of revenue(4,162)(4,069)(4,101)(4,356)(6,159)(6,454)(6,406)(8,451)(12,858)(12,037)

Selling, general & administrative(5,062)(4,870)(5,332)(5,150)(5,730)(5,368)(5,414)(6,179)(7,096)(7,050)

Total operating expenses(13,197)(12,876)(13,484)(13,688)(16,285)(18,340)(16,757)(20,293)(26,166)(27,671)

Operating income9,7949,97310,2639,6749,1397,6399,5667,8977,2589,080

Interest expense(1,260)(1,304)(1,392)(1,289)(1,262)(1,197)(1,406)(2,875)(3,155)(2,755)

Interest & investment income—————111271,200510408

Other income (expense), net629928674753256259(814)2,8335062,651

Pre-tax income9,1639,5979,5459,1388,1336,7017,3467,8554,6098,976

Income tax expense(1,441)(7,618)(1,151)(1,296)(869)(808)(794)(1,138)(519)(1,265)

Net income7,7221,9798,3947,8427,2645,8936,5526,7174,0907,711

EPS — basic$10.32$2.71$12.70$12.96$12.40$10.34$12.18$12.56$7.62$14.33

EPS — diluted$10.24$2.69$12.62$12.88$12.31$10.28$12.11$12.49$7.56$14.23

Shares outstanding — basic (M)748731661605586570538535537538

Shares outstanding — diluted (M)754735665609590573541538541542

Showing the latest 10 of 19 fiscal years.

Source: SEC EDGAR XBRL company facts — figures as reported in each period's original filing (structured data begins ~2008). EPS and other per-share figures are as reported and are not adjusted for later stock splits; a ⚑ marks a period where the reported share count changed by a large factor. Dollar figures in millions unless per-share. Line items a company never reports are omitted. Where a filer switched XBRL concepts, the successor concept is used and definitions can differ slightly (e.g. cash may include restricted cash; banks' revenue is net of interest expense; cost of revenue may exclude D&A; net income may be the amount available to common stockholders; debt issued/repaid may be net of issuance costs or include finance-lease obligations — each only where the original concept stopped being reported). Click a period header to open that period's source filing on EDGAR.